Syndax appoints Richard Shea chief financial officer
Mr. Shea has more than 30 years of experience in a range of financial and advisory roles in the biotechnology industry, most recently serving as Senior Vice President and Chief Financial Officer of Momenta Pharmaceuticals, Inc. as well as the chair of the Audit Committee of Syndax's Board of Directors.
Before being named Senior Vice President and Chief Financial Officer of Momenta in July 2007, Mr. Shea served as its Vice President and Chief Financial Officer since October 2003.
Prior to joining Momenta, he served as Chief Operating Officer and Chief Financial Officer of Variagenics Inc., a publicly traded pharmacogenomics company, that was merged with Hyseq Pharmaceuticals Inc., and as Vice President, Finance of Genetics Institute, Inc., a publicly traded biotechnology company, which was acquired by Wyeth Pharmaceuticals, Inc., which was then acquired by Pfizer, Inc.
Mr. Shea received an A.B. from Princeton University and an M.B.A. from the Public Management Program at Boston University.
Upon the effective date of his appointment as the Company's Chief Financial Officer, Mr. Shea will resign from his positions as a member of Syndax's Board of Directors and as Chair of the Audit Committee of the Board of Directors.
The Company's Board of Directors has elected Pierre Legault as the Chair of the Audit Committee to replace Mr. Shea.